The present invention generally relates to the transdermal delivery of various compounds. In some aspects transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof and optionally a hostile biophysical environment and/or a nitric oxide donor. In some cases the composition may be stabilized using a combination of a stabilization pol...

The invention provides methods of treating nitric oxide/cGMP pathway-cell adhesion disorders and related pharmaceutical compositions diagnostics screening techniques and kits. In one embodiment the invention relates to a method for down-regulating ?4?1-integrin affinity and inhibiting and reversing adhesion formation in patients or subjects in need using a nitric oxide donor.

The present invention relates to microalgae having high efficiency and ability to remove carbon dioxide and the use thereof. More specifically the invention relates to Scenedesmus producto-capitatus microalgae having high carbon dioxide fixation rate and the use thereof. The microalgae of the invention have a high carbon dioxide fixation rate and excellent resistance even to high concentrations of carbon dioxide sulfur oxide (SOx) and nitric oxide (NOx) and are rich in biomass and thus can be ad...

The present invention generally relates to compositions and methods for transdermal drug delivery including treatment and prevention of learning and memory disorders and enhancement of learning or memory. In some cases the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin such as phosphatidylcholine. In certain embodiments the lecithin is present in liposomes micelles or other vesicles containing nitric oxide. The composition can tak...

Shilajit in a standardized composition produces a significant improvement in several cardiovascular parameters including RI AIx and SEVR. Further significant reductions in malondialdehyde and increases in nitric oxide levels are provided suggesting improvement in endothelial function. Shilajit may be used to reduce inflammatory biomarker HsCRP levels significantly compared to baseline and placebo. Additionally Shilajit can provide significant improvement in lipid parameters including total chole...

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis hypertension sickle-cell anemia or other conditions. In some cases the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin such as phosphatidylcholine. In certain embodiments the lecithin is present in liposomes micelles or other vesicles containing nitric oxide. The composition can take the form of a gel ...

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of acne or other conditions. In some cases the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin such as phosphatidylcholine. In certain embodiments the lecithin is present in liposomes micelles or other vesicles containing nitric oxide. The composition can take the form of a gel a cream a lotion an ointment a solution a so...

The present invention generally relates to compositions and methods for treatment of skin and/or other soft tissues that are infected with bacteria such as Staphylococcus aureus and/or other infectious organisms. In some cases the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin such as phosphatidylcholine. In certain embodiments the lecithin is present in liposomes micelles or other vesicles containing nitric oxide. The composition...

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of neuropathic pain or other conditions. In some cases the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin such as phosphatidylcholine. In certain embodiments the lecithin is present in liposomes micelles or other vesicles containing nitric oxide. The composition can take the form of a gel a cream a lotion an ointment a s...